Week 1 HW: Final Project Ideas

HTBAA Homework #1

Q1. What do you want to make?

I am making a scalable platform that uses optics and genetics to create light-responsive spatial images, also known as bacterial photography. This includes engineering biosensors and biocircuits that report as fluorescent proteins, as well as designing biofilm materials that record images based on spatial patterns of light and dark.

The Photoplasm device I created in HTGAA ‘26 has become a key component of the Genspace Community Project focused on synthetic biology and optogenetics. This activity aligns well with the original project, where I went from initial design (Aim 1)to an open-source build and test cycle (Aim 2).

We are now in week 14 of the community project, and the device has evolved closer and closer to a prototype that is suitable for Aim 3: scaling the device to the larger community.

Link: Genspace Community Project

Photoplasm projecting image on plate

HTBAA is a perfect fit and natural progression for Photoplasm. We are actively in the design, build, test and analyze phase; We have data, successes, failures and end-user feedback.

I would like to branch the project into a cloud lab ecosystem where I may design and manufacture a cell-free protein system with a biofilm, as well as a living-cell culture that could reach industrial scale through automation. I will compare both to see which has the strongest application.

Q2. What living system could make it?

The current construct targets use of E. coli for the purpose of achieving a calibrated system that can create spatial images, as the baseline. Since the system is an incubator and light projector, the ability to grow and test different engineered microbes means that we can open up the path for experiments that use light-responsive and light-repressive circuits.

pDawn light responsive circuit

For example, we are currently using pDawn, since it represses transcription from the promoter for DsRed in the dark and, under ~470 nm blue light, begins to glow — based on the amount of light reaching an agar flood plate through a patterned image mask; like a film negative, but digital. We also have BioLight_GenV10, which is a clonal gene synthesized by Twist Bioscience — the culmination of Aim 1, and the start of Aim 2 once we quantify the device performance with pDawn and have created protocols for wet lab use in the community lab.

Q3. How could automation help you make it?

This is a two-part answer. Part 1 is the effective techniques of an automated provider like Twist Bioscience for a clonal gene. Part 2 is what happens after we have identified a strong candidate for propagation. I fully expect to achieve an image in a bacterial culture in the next 12 weeks, through the wonderful collaborative efforts with the Genspace Community Lab Project.

The automation I am referring to here is the propagation of the selected cultures into an increasing number of plates that can be used by local and remote participants experiencing Photoplasm. Rather than creating a stockpile, which can be expensive and carries a high risk of contamination or expiration, I want to explore on-demand plate making, exposure, incubation, visual monitoring in a closed loop, with data analysis — to optimize the system in near real time.

As stated in Aim 3 of Photoplasm, the collective neural network of active devices will contribute to the knowledge base of community participants, which range from curious new learners to expert scientists striving to achieve experimental results.

Q4. What would it take to make it at a meaningful scale?

To make this solution at a meaningful scale, I am following a methodology known as Design Thinking, where the persona of the end user comes first. Who is the target audience? What is the competitive and complementary landscape? What are the risks of not doing this?

I have built a fully functioning prototype of Photoplasm v1.0, which helped to identify essential updates ranging from safety, cost, mechanical, electrical and code-based rapid improvements. The scalability model is focused on going purposefully from rapid prototype to a streamlined manufacturing process.

Photoplasm 1.0 in Enclosure

There is an important intermediate phase. The open-source version of Photoplasm is deemed just that — a fully open-source platform for anyone with access to GitHub to download. It is now supported by a robust interactive build guide, which has become a primary focus. If someone learns how to make one themselves, the scalability is inherent and individualized.

From a commercialization perspective, I am introducing a branch of the open-source project that strives to optimize, resize, and adapt to a robotic automation platform. Both can exist in harmony, as they have the same purpose only at different scale. For the open-source DIY version, it is fully accessible and has a learning component. For the high-volume automated production process, the medical-device-grade product can conduct rapid assays and would be fully compatible with the Reconfigurable Automation Cart platform.

There is even an exciting branch of the open-source project where I am building my own virtual cloud lab for prototype 1.0, which means that remote participants can experience Photoplasm from anywhere, leading to hybrid learning opportunities.

HTBAA and my final project are focused on scalability through emerging cloud labs, with potential for cell-free protein systems to greatly increase scalability and productivity, and to launch a massively adopted optogenetics platform for learning and industrial use.

(1) What you would like to biomanufacture and why?

Describe the target product or output you would like to make. Why are you interested in making it? Your motivation might be utilitarian — for example, addressing a problem in health, sustainability, food, energy, or manufacturing — but it does not need to be. Your project might instead have a social, cultural, artistic, or personal motivation. Clearly articulate what you want to make, who or what it is for, and why you think it is interesting or important.

Now that we have described a platform for optogenetics in cloud labs, I want to focus on the essential construct: a light-responsive cell-free system that can be applied to a substrate suitable for use in the next evolution of Photoplasm.

Think of this as a type of film with specific characteristics, similar to how the photographic film industry used batch manufacturing of film. For example, if we were targeting a therapeutic application, the resulting substrate may use the same light-responsive biocircuit to deliver a manufactured product on demand — reducing overproduction, increasing shelf life, and personalizing the delivery.

I want to biomanufacture a cell-free system that is light-responsive and has the ability to modify the reporter to be fluorescent, with digital images as the observable record. Then, lean into reporters that bind to materials as a substrate of record.

My primary focus is on the creation of photographic fine art, to bring social awareness and accessibility to the community through venues such as makerspaces, wet labs, galleries, and museums. Not just my own fine art, but the creative expression of the wider public audience — very much how photography has been used to capture moments. This may be our synthetic biology moment, made possible by cloud automation.

My “why” goes back to the Design Thinking approach to understanding the persona — the named person who would benefit from the product. A learner exploring their career path; an artist seeking inspiration from nature; a maker building a tool for exploration; and an accessible experience for people of varying abilities, that is, Universal Design.

My personal interest in automated biomanufacturing would be greatly enhanced by observing a live facility, to better understand the scale, operating requirements, and engineering knowledge.

(2) What living system would you use?

Propose at least one living-system manufacturing chassis that could produce your target — for example, a microbial, mammalian, or cell-free system. At a high level, describe how the system would make your target product. What goes into the system? What biological process or processes occur? What comes out? You do not need to design the complete biological system yet. Make reasonable assumptions where necessary and identify them.

I think a cell-free protein system applied to a biofilm will become a primary use case, and the use of E. coli as a living cell may become an economical and scalable automation solution. So there are two unique constructs to use. I will be researching exactly how we may go from a cell-free reagent to a material substrate that can hold an image.

Biofilm in this instance is any substrate coated or manufactured with a light-responsive surface: an agar lawn, a paper-based lawn, or even a ceramic coated with a sample. The cell-free protein system would be activated by distilled water and produce a recorded image on a variety of materials.

When I refer to the substrate, I intend to make my own paper and apply an agarose medium with a bacterial flood, to see if I can record an image onto recycled mashed fiber paper — which in itself is a fine art medium.

A cell-free protein system could help to accelerate an automated production process. I am very interested in pDawn-Ag43, since that means we continue our pDawn calibration with regard to swappable fluorescent reporters and a swappable structural output.

I am specifically interested in the calcium carbonate and curli route: I have been exploring the use of clay with kiln-fired glazes that react with biochemical residues to create highly expressive color mutations in a permanent, fired medium. We have a kiln, we have glaze, and we have Photoplasm — another reason why we need a way to biomanufacture the light-responsive spatial imaging systems.

The “take something with you” mentality applies to the need for a physical artifact, when created by the individual. That defines the experiential process and artistic expression. Virtual and digital expreiences can also lead to an artifact, such as a shared image which will be available through camera optics found in the device.

The cell-free system is the light-sensing element, with a promoter and a fluorescent reporter: a DNA sequence transcribed and translated to protein in a cell-free protein synthesis reaction. From an example perspective, putting a cell-free reaction into a substrate and exposing it to light may lead to a unique definition of a recorded film layer.

I am steering away from spores and mycelium at this level, though an inert form may lead to a follow-on discussion. Again, keeping scope closer to the production of a digital image or a manufactured substrate as the permanent record.

We are currently using pDawn as the calibration reference. My own construct, BioLight_GenV10, is a clonal gene synthesized by Twist Bioscience; its design source is the eLightOn system of Li et al. I want to make a plasmid with cut sites that rely on Golden Gate or Gibson assembly, to be able to try different reporters. The 470 nm figure is the input — it is what Photoplasm currently emits.

Photoplasm 1.0 Device Simulator

(3) How would you use automation?

Identify at least one automation technology that you would combine with your living system. This could include a large-scale Cloud Lab, a desktop liquid-handling robot such as an Opentrons, a programmable microfluidics platform such as Nuclera’s, or another automation technology. Describe what part of the biomanufacturing workflow you would automate and why. For example, you might automate liquid handling, culturing, assembly, screening, sampling, measurement, optimization, or another step.

The RAC is the Robotic Automation platform from Ginkgo Bioworks — the Reconfigurable Automation Cart. The use of Twist is fully compatible, as they synthesize clonal genes which would be the provider for my downstream colony propagation or other synthetic biology constructs including cell-free systems.

I am seeking to use Ginkgo’s RAC system to create plates with an agarose lawn containing my engineered and selected light-responsive culture. Then, through petri dish handling robotics, transfer into a cylindrical light-emitting projector, the Photoplasm “Beam.” The device includes an incubator module. I may be able to modify the device to reside inside an existing incubator RAC module, leading to multiple runs in one enclosed unit. The Photoplasm “Beam” is a branch, and will contain its own optical stack, deviating from the original 1.0 darkroom enlarger into a fully self-contained manufacturing specification. The addition of RAC protocols means the design will be directly influenced by — and integrated with — the RAC from the start: the beginning of device development with a standardized automation platform. There will always be an open-source “builder” version using petri dishes. I do like the idea of a rectilinear mode for well plates, but I still see potential in the petri dish form factor — the analogy is to photographic film formats, small, medium and large: 35 mm, 4×5, 2¼ square. We will likely stay round as an aesthetic.

Photoplasm 1.0 Interactive 3D Visualization

The key is to provide repeatable, automated plating and light-responsive spatial imaging in a robotic pipeline, to increase consistent throughput.

The device includes an image monitoring and capture phase, which leads to remote monitoring. There is no human in the readout; camera sensors in the “Beam” do the work. It is a neural network of connected Photoplasm devices, with opt-in — or out — to participate in a larger knowledge base. The device will capture logs that can also be used for diagnostics in a customer support model.

(4) How much would you need to make, and how long would it take?

Perform a back-of-the-envelope calculation estimating what it would take to manufacture your target at a meaningful scale.

(a) How much? Define a scale relevant to your project and calculate approximately how much of your target product you would need to manufacture. If you are producing an art or design artifact, define an appropriate scale yourself. Clearly show your calculation, including units, assumptions, and sources for important numbers.

The scale for this project is: how many light-responsive exposures can be incubated? In a wet lab, one at a time, with one machine, operator attended — that is about 2 per a normal eight-plus-hour day, five days a week. With automation, the system runs 24/7, so one device can produce 4–6 images per day, seven days a week. With two machines and an optimized metabolic load, perhaps we strive for 3 hours for a high-contrast, high-fold-ratio result, running 24×7 with an image queue in the automation pipeline. There is a linear curve as more devices are introduced, but the data set grows with every shared result.

Photoplasm 1.0 Exposure Time

A typical roll of film was 36 exposures, limited by the length of film compacted into a light-tight canister. That is the unit adopted here: one roll = 36 exposures, and the production target is one roll per day. In our model, a group of 6 each making one image in a classroom or group setting means that every day we can create one image every 4 hours with one purpose-made device. If we had 6 devices, or “Beams,” in an automated RAC, we could reach 36 images per day. So building one locally and six remotely means a group of six can build, calibrate and test, then quickly ramp up.

Exposures. A month is 30 operating days and a year 365 for the automated rows; the attended row runs 21.7 working days a month and 260 a year.

One exposure = one flood plate = one image. Cycle time is an anticipated 4–6 hours for exposure on flood plates; actual time will be observed. Throughput figures assume 24/7 operation and 100% yield.

The 4–6 hour cycle is cited from pDawn from The ODIN, a bacterial culture that expresses DsRed. For BioLight_GenV10, the design source is Li et al.’s eLightOn system, which indicates a 4–6 hour incubation with a duty cycle of light on/off pulses to support the ratio of light-emitting protein to non-emitting protein. The definitive answer will come from our calibration protocol.

If we host the device in the cloud, that is a fixed throughput that can grow as demand increases. If someone wants to build the open-source device, they may benefit from repeated cloud experiments. The platform then becomes a DIY kit — which is where a non-replicating cell-free system comes in, as a differentiator: it ships no living organism, so it reaches venues a living-system kit cannot. The ability to ship as a kit to a school with an educational component means that optogenetics reaches the classroom, and the cloud lab is waiting for your next scalable production: a pipeline that extends into the community and feeds the cloud lab. Low volume, high cost for the cell-free route; high volume, low cost for living cells. Both are applicable.

(b) How long? Using your proposed living system and automation technology, estimate how long it would take to manufacture that amount. Consider quantities such as production rate, yield, volume, number of parallel experiments or reactors, automation throughput, or whatever parameters are most appropriate for your system. You may discover that the automation technology you would use to prototype your system is very different from what you would use to manufacture at scale. If so, describe both.

At six devices on a 4-hour cycle, one roll of 36 exposures takes one day.

In rolls, at six devices on a 4-hour cycle: one roll per day, 30 rolls per month, 365 rolls per year. At the 3-hour target: 40 rolls per month and 487 per year.

These differ in kind, not degree. Photoplasm 1.0 is built upon a retrofitted photographic darkroom enlarger, operated by hand. The Beam is designed for automation from the first drawing, with its own optical stack and a self-contained manufacturing specification, integrated with a standardized automation platform from the start.

“One-day Photoplasm Lab” is very similar to the one-hour photo lab model.

(5) What don’t you know yet?

After completing your analysis, identify the 2–3 biggest technical unknowns, bottlenecks, or assumptions in your proposed biomanufacturing system. What would you need to learn, measure, or experimentally determine to know whether your idea could actually work?

What does success look like? Material handling of a form factor through the RAC system. Can we load a cylindrical “Beam” with success? This precedes the biological experimentation, and it can be modeled and achieved in less than 14 weeks. In parallel, we explore the synthetic biology and proceed with the community optogenetics project, to inform the result.

My next unknown will be related to cell-free systems. What sequence I choose will be based on research, prior knowledge of canonical systems, cost of manufacturing, and the path to engineering, synthesizing, lysating, reconstituting, and calibrating with the light-responsive device.

Another unknown is what the pipeline would look like to create a living cell culture that has a light-responsive biosensor expressing a color reporter, in a cloud lab infrastructure. What would the cost comparison be to cell-free? With an expectation that living cells may be less expensive to produce, what is the trade-off in terms of accessibility and sustainability outside of a lab? Is there a dual pathway?

In summary, for this section, I will analyze living cell systems and cell-free protein systems in automated cloud labs, to optimize manufacturing time, cost, and quality. This comparison will allow me to make strategic design decisions that could lead to a successful launch of a solution founded on open-source principles, with opportunities for funding models to support delivery at scale.

The definitive answer on cycle time will come from our calibration protocol.

Learning as a Solution

The biomanufacturing pipeline I am proposing is supported by an experiential learning platform, which provides resources that inform the practitioner about optogenetics. The Photoplasm device and synbio concepts reside in a growing online library of connected learning activities which show how to build the device itself, and will include visual explorations of light-responsive genetic circuits and sensors. For HTBAA, I plan on introducing the digital twin of the device for instructional learning, which will lead to wider adoption and understanding, as well as remote operation and simulation. Once the device is built and can be used as a learning tool in a makerspace setting, the ability for participants to create physical artifacts derived from optogenetics supports the idea of “learning by doing.”

Photoplasm 1.0 Interactive eLearning Module

Conclusion

What I am doing is setting the stage for the return of the historical neighborhood photo lab, where you would go get your film developed, then return to pick up your photos — sometimes in an hour or less! If the future of AI and personalized therapeutics stands, one day your corner optogenetics lab will have your order synthesized and waiting. I plan to build out the model and allow innovation to reach the community — in the same way the photo lab and darkroom became a premier creative destination, supported by the photographic industry. In a way, we are going from analog to digital, and back to analog.

HTBAA Homework #1 — Ai Framework with Claude Science (Opus 5)

The authoring framework was defined incrementally by the author across 120 prompts in one session, each new rule stated as an instruction, applied immediately, versioned, and logged — so the method was built from the work rather than imposed on it.

• Session — 120 authored prompts, 1,087 total message records, 32 artifacts, 2026-09-17 to 09-20.
• Agent role — mentor, not author: structure, verification and questions, with no assignment content unless co-authoring was requested, and every rule tagged handout-binding, author-binding or agent-advisory.
• Baseline — the author’s first answers to the four framing questions frozen verbatim, with 10 revisions recorded beneath them as timestamped addenda, for authorship provenance.
• Documents — a clean submission draft in the author’s voice (v1.36) kept separate from a working file, a mentor memory, and a verbatim record of every prompt.

Citations

Original references — provided with the course

Assigned readings and course materials issued with the assignment. Author lists follow the publisher record.

Asin-Garcia, E., Fawcett, J. D., Batianis, C., & Martins dos Santos, V. A. P. (2025). A snapshot of biomanufacturing and the need for enabling research infrastructure. Trends in Biotechnology, 43(5), 1000–1014. https://doi.org/10.1016/j.tibtech.2024.10.014

Averesch, N. J. H., Berliner, A. J., Nangle, S. N., Zezulka, S., Vengerova, G. L., Ho, D., Casale, C. A., Lehner, B. A. E., Snyder, J. E., Clark, K. B., Dartnell, L. R., Criddle, C. S., & Arkin, A. P. (2023). Microbial biomanufacturing for space-exploration—what to take and when to make. Nature Communications, 14, 2311. https://doi.org/10.1038/s41467-023-37910-1

Petzold, C. J., & Mukhopadhyay, A. (2025). From bench to biofactory: High-throughput technologies and automated workflows to accelerate biomanufacturing. Current Opinion in Biotechnology, 94, 103320. https://doi.org/10.1016/j.copbio.2025.103320

Rasor, B. J., Vögeli, B., Landwehr, G. M., Bogart, J. W., Karim, A. S., & Jewett, M. C. (2021). Toward sustainable, cell-free biomanufacturing. Current Opinion in Biotechnology, 69, 136–144. https://doi.org/10.1016/j.copbio.2020.12.012 ¹

Yap, W. S., Choudhury, D., & Suntornnond, R. (2023). Towards biomanufacturing of cultured meat. Trends in Biotechnology, 41(3), 292–294. https://doi.org/10.1016/j.tibtech.2023.01.014

Ye, J.-W., Lin, Y.-N., Yi, X.-Q., Yu, Z.-X., Liu, X., & Chen, G.-Q. (2023). Synthetic biology of extremophiles: A new wave of biomanufacturing. Trends in Biotechnology, 41(3), 342–357. https://doi.org/10.1016/j.tibtech.2022.11.010

Zhang, Y.-H. P., Sun, J., & Ma, Y. (2017). Biomanufacturing: History and perspective. Journal of Industrial Microbiology & Biotechnology, 44(4–5), 773–784. https://doi.org/10.1007/s10295-016-1863-2

How to BioManufacture (Almost) Anything — Class #1 Reading List [Annotated project reading list]. Internal working document.

Conducted research — located during this work

Sources found independently in the course of answering the assignment, resolved against GenBank, Crossref, PubMed and Europe PMC rather than from recall.

Ginkgo Bioworks. (n.d.). Hardware — RACs & Tiles. https://www.ginkgo.bio/product/hardware

Ginkgo Bioworks. (n.d.). Yeast heat shock transformation on a flexible Reconfigurable Automation Cart (RAC) system [Tech note]. https://www.ginkgo.bio/tech-notes/yeast-heat-shock-transformation-on-a-flexible-reconfigurable-automation-cart-rac-system

Gregorio, N. E., … Oza, J. P. (2020). Unlocking applications of cell-free biotechnology through enhanced shelf life and productivity of E. coli extracts. ACS Synthetic Biology, 9(4). https://doi.org/10.1021/acssynbio.9b00433

Huang, A., … Collins, J. J. (2018). BioBits Explorer: A modular synthetic biology education kit. Science Advances, 4(8), eaat5105. https://doi.org/10.1126/sciadv.aat5105

Huang, A., … Stark, J. C. (2022). Implementing hands-on molecular and synthetic biology education using cell-free technology. Methods in Molecular Biology. https://doi.org/10.1007/978-1-0716-1998-8_25

Jayaraman, P., Yeoh, J. W., Jayaraman, S., Teh, A. Y., Zhang, J., & Poh, C. L. (2018). Cell-free optogenetic gene expression system. ACS Synthetic Biology, 7(4), 986–994. https://doi.org/10.1021/acssynbio.7b00422

Möglich, A. (n.d.). pDawn (Plasmid #43796) [Plasmid]. Addgene. http://n2t.net/addgene:43796 (RRID:Addgene_43796)

Multamäki, E., et al. (2022). Optogenetic control of bacterial expression by red light. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.2c00259

Expression vector pDawn, complete sequence (GenBank accession JN579121.1) [Nucleotide record]. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/nuccore/JN579121.1

Ohlendorf, R., Vidavski, R. R., Eldar, A., Moffat, K., & Möglich, A. (2012). From dusk till dawn: One-plasmid systems for light-regulated gene expression. Journal of Molecular Biology, 416(4), 534–542. https://doi.org/10.1016/j.jmb.2012.01.001

Shivakumar, T., … Williams, P. M. (2025). A design of experiments approach for enhancing room temperature stability of a lyophilised and paper-based bacterial cell-free system. Bioengineering, 12(3), 223. https://doi.org/10.3390/bioengineering12030223

Smith, M. T., … Bundy, B. C. (2014). Lyophilized Escherichia coli-based cell-free systems for robust, high-density, long-term storage. BioTechniques, 56(4), 186–193. https://doi.org/10.2144/000114158

Stark, J. C., … Jewett, M. C. (2018). BioBits Bright: A fluorescent synthetic biology education kit. Science Advances, 4(8), eaat5107. https://doi.org/10.1126/sciadv.aat5107

Stark, J. C., … Jewett, M. C. (2019). BioBits Health: Classroom activities exploring engineering, biology, and human health with fluorescent readout. ACS Synthetic Biology, 8(5). https://doi.org/10.1021/acssynbio.8b00381

Williams, L. C., Gregorio, N. E., So, B., Kao, W. Y., Kiste, A. L., Patel, P. A., Watts, K. R., & Oza, J. P. (2020). The Genetic Code Kit: An open-source cell-free platform for biochemical and biotechnology education. Frontiers in Bioengineering and Biotechnology, 8, 941. https://doi.org/10.3389/fbioe.2020.00941

Yang, J., & Lu, Y. (2022). Optical sensing in cell-free expression. Methods in Molecular Biology, 2433, 343–349. https://doi.org/10.1007/978-1-0716-1998-8_21

Zhang, P., Yang, J., Cho, E., & Lu, Y. (2020). Bringing light into cell-free expression. ACS Synthetic Biology, 9(8), 2144–2153. https://doi.org/10.1021/acssynbio.0c00211

Week 2 HW: DNA Design

HTBAA Homework #2 — Final Draft

pColorWheel: Light-Patterned Biomanufactured Paper

Popcorn Pop Art Generator

Project Summary

The pColorWheel project crystallized through 12 major design decisions. The path moved from building Popcorn (an SBOL-inspired simulator) while awaiting Kernel access, to obtaining access and shifting to live Kernel part creation, to recognizing that the subtractive color mechanism required three integrated layers (living biofilm → cell-free synthesis → paper substrate), to establishing paper production as the core platform with ceramics as a secondary extension.

The final construct design builds on pDawn (Jin & Riedel-Kruse 2018) for light-responsive biofilm patterning and engineered curli (Nguyen et al. 2014) for programmable surface display. The build strategy (synthetic order for calibration → Gibson assembly for modular exploration → chip synthesis for scale) balances validation with scalability.

The three core unknowns are all tied to making the paper production work: pH-indicator response, spatial resolution, and color stability.

Part 0 — Kernel Setup

Where are you building this?

I logged into Asimov Kernel through a prior Genspace account and joined the HTBAA 2026 workspace. My project repository is HTBAA26_Genspace and my folder is Eric Schneider. I used Kernel to deconstruct existing parts from pDawn-sfGFP and to begin prototyping the two-reporter constructs.

Part 1 — Define Your Expression Target

What molecules are you expressing, and where do they come from?

I am expressing two reporters, one for each color space. For additive light (fluorescent, emitted), the reporter is sfGFP from pDawn-sfGFP. For subtractive light (pigment on substrate), the reporter is CsgA, the major curli subunit from E. coli K-12. Both are expressed under blue-light control (pDawn, 470 nm, YF1/FixJ).

Detailed Answer

Additive reporter — sfGFP (fluorescent protein):

• Source: pDawn-sfGFP (Addgene #107741), published in Jin & Riedel-Kruse, PNAS 115(14):3698–3703 (2018)
• Backbone: GenBank JN579121.1 (Ohlendorf et al., 2012)
• Size: 238 amino acids
• Behavior: Stays soluble in cytoplasm, emits light under 488 nm excitation
• Light control: Blue-light responsive promoter (pDawn), YF1-FixJ photoreceptor system

Subtractive reporter — CsgA (curli structural protein):

• Source: UniProt P28307 (csgA, E. coli K-12 MG1655)
• Sequence: RefSeq NC_000913.3, 151 amino acids
• Signal peptide: Residues 1–20 (secretion signal)
• Behavior: Secreted, self-assembles into amyloid nanofibers on cell surface
• Host requirement: csgA-deletion strain that retains the rest of curli export machinery (CsgG, CsgE, CsgF, CsgB nucleator)

Key distinction: Both are proteins, but distinguished by what they do and where they go. The additive reporter is fluorescent and cytoplasmic (light-emitting). The subtractive reporter is structural and surface-deposited (light-absorbing/reflecting, building a physical spatial record).

Chassis: Single host (E. coli K-12) drives both outputs via the same blue-light control layer (470 nm).

Part 2 — Design Your Genetic Parts

What are the parts you will use to build these constructs?

The parts are: pDawn promoter (blue-light responsive), RBS (Shine-Dalgarno, E. coli standard), sfGFP coding sequence (238 aa), CsgA coding sequence (151 aa with signal peptide), rrnB T1 terminator, pBR322 origin, and kanR selection marker. All parts are standard prokaryotic parts compatible with E. coli cloning.

Parts Register

All parts created in Kernel with correct types (Promoter, RBS, CDS, Terminator, Origin, Marker) and registered in the parts library.

Part 3 — Assemble Your Construct

How do the parts go together in the final constructs?

The pDawn-sfGFP construct has the pDawn promoter, RBS, sfGFP CDS, and terminator in series, ending in the pBR322-kanR vector backbone. The pDawn-CsgA construct is identical except CsgA replaces sfGFP. Both are assembled in 5’ to 3’ order with reading frames checked: ATG start, no internal stops, TGA/TAA/TAG stop.

Construct Assembly

pDawn-sfGFP:

pDawn-promoter → RBS → sfGFP (238 aa) → rrnB-T1 → [vector: pBR322-kanR]

pDawn-CsgA:

pDawn-promoter → RBS → CsgA (151 aa, signal peptide 1–20) → rrnB-T1 → [vector: pBR322-kanR]

Quality check: Reading frame verified — ATG start → no internal stop codons → TGA/TAA/TAG stop.

[AUTHOR CAVEAT: Construct maps will be rendered and exported from Kernel as part of the D3-FINAL workflow. Schematic placeholder pending Kernel export.]

Part 4 — Optimize and Quality-Check

How do you optimize the constructs and verify safety?

Kernel runs codon optimization (avoiding BamHI/XhoI sites, maintaining 45–55% GC, eliminating rare codons), BLAST search against NCBI nr and UniProt databases, and a safety screen for pathogenic sequences or toxins.

Expected Results

Codon optimization (pending Kernel execution):

• Constraints: No BamHI/XhoI sites (preserve MCS), GC content 45–55%, no rare codons
• sfGFP: 238 aa → optimized
• CsgA: 151 aa → optimized

BLAST search (pending Kernel execution):

• sfGFP: Expected 100% match to Aequorea victoria GFP (UniProt P42212)
• CsgA: Expected 100% match to E. coli K-12 csgA (UniProt P28307)

Safety screen (pending Kernel execution):

• pDawn-sfGFP: No pathogenic sequences, antimicrobial resistance, or toxin systems flagged. pBR322 and kanR are standard non-pathogenic markers.
• pDawn-CsgA: No flagged concerns. CsgA is a structural biofilm protein, not a virulence factor.

[AUTHOR CAVEAT: Kernel tools (codon optimization, BLAST, safety screen) were planned but not executed in this draft. These sections reflect expected processes pending actual Kernel workflow execution. Per framework §3, an honest caveat about what could not be run is acceptable.]

Part 5 — From Design to Build

Popcorn Pop Art Generator

What is the biomanufacturing platform, and how will you build it?

pColorWheel is a light-patterned biological paper made from three integrated layers: living cell biofilm patterned under blue light, cell-free protein synthesis producing colored proteins that bind the biofilm, and paper substrate pre-coated with pH-responsive indicator that develops color when the cell-free reaction diffuses into the fibers. Build method: synthetic DNA order (Addgene) for calibration, Gibson assembly for modular exploration, chip oligo synthesis for scale.

The Platform

The primary deliverable is a light-patterned biological paper — a biomanufactured material made from living E. coli cells and cell-free protein synthesis.

Three integrated layers:

1. Living cell layer: Cells expressing pDawn-CsgA pattern a biofilm under blue light (470 nm). CsgA self-assembles into amyloid nanofibers on the cell surface, creating a spatial map of the light pattern.

2. Cell-free color layer: A cell-free protein synthesis (CFPS) reaction produces a colored protein (GFP-family chromoprotein or pH-responsive indicator) that binds to the deposited curli biofilm.

3. Paper substrate layer: Pre-coat paper with a pH-responsive indicator. When CFPS reaction runs with distilled water as carrier, reaction outputs (pH shift, metabolites, color-binding proteins) diffuse into the paper matrix and trigger color development in the fibers. The color is made within the paper, not added to it.

Platform value: Encodes biological information into a solid-state material. The light pattern controls what gets made and where; CFPS + paper substrate scale the output.

Ceramics is a secondary artistic extension: patterned paper can be fired with collaborators to create permanent glazed versions, but the core platform’s value is paper production itself.

Build Strategy: Staged Synthesis

Phase 1 — Calibration (synthetic DNA order from Addgene): Order complete pDawn-sfGFP and pDawn-CsgA constructs as synthesized DNA (Twist Bioscience, IDT). Baseline calibration — verified sequences that establish light-response dynamics and biofilm patterning before additional complexity.

Phase 2 — Modular assembly (Gibson assembly or Golden Gate): Once calibration constructs are working, introduce genes of interest (alternative chromoproteins, binding domains, pH-responsive proteins). Gibson assembly enables in-frame fusion of new CDS into MCS; Golden Gate allows hierarchical cloning of multiple parts in one reaction.

Phase 3 — Reagent-driven color expression: Final construct optimized for cell-free protein synthesis and tested with pH-indicator paper substrate. CFPS reaction conditions tuned to paper’s pre-coating chemistry and chromoprotein’s maturation kinetics.

Synthesis Feasibility

Both constructs are ~4.5–5 kb (pBR322 backbone ~4.4 kb + sfGFP 0.7 kb or CsgA 0.45 kb + regulatory sequences 0.2 kb), well within the standard synthetic DNA order limit (10 kb). No GC-rich regions, poly(A) tracts, or problematic secondary structures expected.

Constraints applied: Codon optimization, no internal BamHI/XhoI sites, no rare codons, GC content 45–55%.

Assembly viability: Fragment-based Gibson assembly is viable — pDawn-MCS can be synthesized as fragments (5’ promoter-RBS, middle CDS, 3’ terminator-vector) and assembled in one reaction. Chip-based oligo synthesis (Kosuri et al. 2010, Tian et al. 2004) is also viable for production scale — 5 kb constructs are routine for programmable DNA synthesis, and modular structure maps cleanly to oligo tiling and error correction.

Part 6 — What Don’t You Know Yet?

What are the three biggest technical unknowns?

Unknown 1: Does the pH-indicator paper actually respond to the CFPS output? Unknown 2: Does the spatial resolution of the light pattern survive diffusion through biofilm and paper? Unknown 3: How stable is the color over time and environmental conditions?

Unknown 1: pH/Reagent Response in Paper Matrix

The problem: CFPS produces a pH shift and metabolites. Pre-coated paper carries an indicator that changes color within a pH range. Does diffusion into the matrix and indicator activation produce visible, stable color?

How to find out: Run CFPS reaction in contact with small pieces of pre-coated pH-indicator paper (calibrated to expected CFPS pH range). Image paper over time to measure color intensity and spatial uniformity. Compare different indicator coatings (anthocyanins, bromocresol green, pH-responsive dyes) to find the best reporter for CFPS kinetics.

Unknown 2: Spatial Resolution Through the Pipeline

The problem: Light pattern controls biofilm at ~25 µm resolution (pDawn biofilm lithography). Does that pattern survive transfer to CFPS (diffusion into cell-free reaction) and then to paper (diffusion into fibers), or does it blur?

How to find out: Pattern pDawn-CsgA biofilm under controlled illumination (stripes, grids, or image projected via Beam device). Run CFPS on biofilm in contact with pH-indicator paper. Image resulting paper at high magnification (confocal if fluorescent, optical microscopy otherwise) and measure edge sharpness of color transitions. Correlate against original light pattern to quantify resolution loss.

Unknown 3: Color Stability and Environmental Persistence

The problem: How long does color remain stable in paper? Over what timescales (hours, days, weeks)? Under what conditions (light, humidity, temperature)? “Permanent biological record” requires stability over months or years.

How to find out: Make patterned papers with different indicator coatings and CFPS color proteins. Store samples in controlled conditions (dark, ambient light, 4°C, room temperature, 37°C, varying humidity) and measure color intensity and hue retention periodically. Run accelerated stability tests (light exposure, moisture cycling, heat) to predict long-term stability.

Citations

Primary Literature

Gibson, D. G., et al. (2009). Enzymatic assembly of DNA molecules up to several hundred kilobases. Nature Methods, 6(5), 343–345. https://doi.org/10.1038/nmeth.1318

Jin, X., & Riedel-Kruse, I. H. (2018). Biofilm lithography enables high-resolution cell patterning via optogenetic adhesin expression. Proceedings of the National Academy of Sciences, 115(14), 3698–3703. https://doi.org/10.1073/pnas.1720676115

Kosuri, S., et al. (2010). Scalable gene synthesis by selective amplification of DNA pools from high-fidelity microchips. Nature Biotechnology, 28(12), 1295–1299. https://doi.org/10.1038/nbt.1716

Nguyen, P. Q., et al. (2014). Programmable biofilm-based materials from engineered curli nanofibres. Nature Communications, 5(1), 4945. https://doi.org/10.1038/ncomms5945

Ohlendorf, R., Vidavski, R. R., Eldar, A., Moffat, K., & Möglich, A. (2012). From dusk till dawn: one-plasmid systems for light-regulated gene expression. Journal of Molecular Biology, 416(4), 534–542. https://doi.org/10.1016/j.jmb.2012.01.001

Course Readings

Elowitz, M. B., & Leibler, S. (2000). A synthetic oscillatory network of transcriptional regulators. Nature, 403(6767), 335–338. https://doi.org/10.1038/35002125

Tools and Databases

Kernel (Asimov). Accessed 2026-09-29 via HTBAA 2026 workspace.

NCBI RefSeq NC_000913.3 (Escherichia coli str. K-12 substr. MG1655, complete genome).

UniProt P28307 (csgA, E. coli).

UniProt P42212 (GFP, Aequorea victoria).

Appendix C — AI use log

Per HTBAA homework framework §3 (R-27): “Please also cite your AI client and prompts.”

Session Summary: 100+ turns (500+ total messages including author questions, AI responses, tool results, revisions, and auditor findings across the full conversation)

This log records all AI interactions used to develop the assignment. Entries are written as the work happens, not reconstructed afterwards. The author’s prompt is quoted verbatim; AI outputs and author actions follow.

Author reflection

The AI’s role evolved from scaffolding (outline + coverage tracker) through elicitation (ask the author the verbatim questions) through co-authoring (build the draft from the author’s answers) to correction (catch citation errors, flag incomplete tool runs, revise for honesty and accuracy). At each step, authorship remained clearly with the author: the AI proposed, the author decided. The framework’s §3 requirement to log and cite AI work kept the boundary transparent.

Key decisions made by the author, not the AI:

• Popcorn simulator + Beam device naming and scope
• Choice of sfGFP (additive) and CsgA (subtractive) reporters
• pDawn blue-light control layer (470 nm) for both
• Paper production as primary deliverable; ceramics secondary
• Staged synthesis strategy (synthetic order → Gibson → chip)
• Part 6 unknowns scoped to paper (pH response, resolution, stability)
• All three core research objectives

The AI served as a research partner and accountability mechanism: finding literature, verifying sequences, organizing the framework, and catching errors. The author owned the science.

Week 3 HW Cell-free reaction design

HTBAA Homework #3

Cell-Free Reaction Design

Part A — Compare cell-free reaction compositions

A1. Why does the concentration of potassium glutamate and magnesium glutamate differ between compositions? Which is more sensitive?

My response.

Because each concentration responds differently to disulfide bonds. For example, in in sfGFP which does not have disulfide bonds, potassium glutamate is more effective at successful folding. Magnesium glutamate is more suited for disulfide bonds as required for Petase and even more so for reteplase

So I am choosing Magnesium for A1 as it provides the reaction energy needed for NTPs

Ok, so adding magnesium is a low cost way to provide a catalyst for the NTP energy source .

I initially attributed the difference between the two salts to disulfide requirement, then to magnesium supplying the reaction energy, before settling on magnesium as a low-cost catalyst.

Feedback. Both salts share the glutamate anion, so the contrast is K⁺ versus Mg²⁺, not the salts. Magnesium is the more sensitive of the two it occupies discrete saturable sites and is chelated roughly 11 by nucleotides and phosphate, so free Mg²⁺ — not added Mg²⁺ — is what the machinery sees, and it operates near 5 mM against potassium’s 270 mM. The first two framings above were tested and discarded neither cation is redox-active, and magnesium is a non-consumed catalyst, not an energy source.

→ Worked analysis, calculations and caveats Appendix E.1.

A2. Explain how a PEP+NTP reaction formulation is different from a Ribose+NMP reaction formulation.

My response.

give me some socratic reasoning around A2 since PEP+NTP different from Ribose+NMP in that one is the energy for transcription and one is the energy for translation. that’s my starting point.

what makes the most sense for me is the pre-made vs in situ process. I believe premade will save energy for other in situ processing.

I proposed a starting frame for the comparison, then replaced it when the first frame did not survive scrutiny.

Feedback. The two formulations differ in whether phosphate-bond energy and nucleotides are bought pre-made or generated in situ — not in which process they feed. Both routes supply both transcription and translation, and translation dominates demand at four phosphate equivalents per peptide bond, so PEP at 30 mM covers only ~39% of one run’s requirement and the remainder comes from metabolism either way. The pre-made route buys a fast start, not a larger total.

→ Worked analysis, calculations and caveats Appendix E.2.

A3. Choose two cell-free reaction compositions from the literature; compare and contrast the choice of reagents and the concentration of reagents.

My response.

for A3, now that we know Mg is important, and is low cost but only provides catalyst, and that kinetic Km sets the floor, we need to look at more impactful tuning levers, that have more kinetic impact AND less cost. GMP seems to be the best focus area to pursue. Let’s test the theory with calculations.

I named a lever and asked for it to be tested numerically rather than asserted.

Feedback. Pair compared PANOx-SP against the cost-optimised RFopt of Olsen et al. The GMP hypothesis was right in direction and wrong in ranking — nucleotide form is the largest coherent lever class, but GTP is third at 15.1% of variable cost, behind PEP at 29.0% and coenzyme A at 22.8%; substituting G, U and C as a class recovers 39.4%. The unexpected result was that a cost substitution silently moves an unrelated optimum the substitution pushes free Mg²⁺ further off target, so nucleotide and magnesium changes are not independent.

→ Worked analysis, calculations and caveats Appendix E.3.

Part B — Design one reaction composition for each of the three proteins

Shared design constraints (Section 2F of the assignment)

Cost anchors (assignment, sourced to Olsen et al. 2026)

Scoring objective cost per gram of functional protein.

Reducing vs oxidizing regime (Section 2C)

Folding difficulty ranking sfGFP (0 disulfides, 2 free thiols) < TfCut2 PETase (1 disulfide) < Reteplase (9 disulfides, all requiring correct pairing).

B1a. sfGFP composition

My response.

for the submittals to the coopetition, it is looking like both PEP and RIBOSE reagents are being made for each of 3

I built the sfGFP composition on the assigned RFopt reference plate, changing five reagents and leaving the rest at reference. The per-reagent rationale is in the table below.

What changed from the source well (full per-reagent table in the appendix)

All other reagents held at the reference value. Designable volume 8,675 nL of 11,000 nL; $0.0263007 per 20 µL reaction; 0 errors, 0 guardrail failures.

Feedback. Five reagents changed, twelve held at reference. The magnesium cut is the mechanistically strongest move, and the AMP trim pays twice — it makes the four nucleotides equimolar and, by removing chelation load, carries free Mg²⁺ onto its optimum at no cost. The cost result is negligible all-in falls 0.49%, because 92% of a reaction is lysate, DNA template and base buffer, none of which is designable.

→ Worked analysis, calculations and caveats Appendix E.4.

B1b. PETase (TfCut2) composition

My response.

I gave PETase the same vector as sfGFP after testing whether any reducing-regime reagent could improve its folding outcome. None could.

What changed from the source well (full per-reagent table in the appendix)

All other reagents held at the reference value. Designable volume 8,675 nL of 11,000 nL; $0.0265907 per 20 µL reaction; 0 errors, 0 guardrail failures.

Feedback. Identical vector to sfGFP. The decision not to diverge is supported rather than assumed all 51 reducing-compatible reagents on the menu were tested at two volumes each and none changed the active fraction. The 57% loss is an unmeasured folding prior, not a formulation fault, and the crystal structure agrees that redox chemistry is not the lever — the single disulfide sits 26 Å from the catalytic serine.

→ Worked analysis, calculations and caveats Appendix E.5.

B1c. Reteplase composition

My response.

let’s compare a more aggressive move on reteplace. make some multiple variable moves to see if we can get cost down in comparison to energy and kinetics

what is the minimum amount of folding we can expect before the choice is not a good candidate

I took a multi-variable approach on reteplase rather than testing one reagent at a time, and set an acceptance threshold from the assay before accepting any design.

What changed from the source well (full per-reagent table in the appendix)

All other reagents held at the reference value. Designable volume 9,350 nL of 11,000 nL; $0.0273835 per 20 µL reaction; 0 errors, 0 guardrail failures. GSSG 4.04 mM and GSH 1.0 mM retained at reference.

Feedback. Order mattered. Removing DsbC alone looks like a bad move until cysteine is fixed first, so one-at-a-time testing would have rejected the correct answer. At the plate’s assigned 5 mM, cysteine acts as a reductant in the DSB regime and modelled pairing falls below the assay’s replicate-safe threshold; with it removed, pairing improves without DsbC at all. Cost falls 206.7× on a single reagent.

→ Worked analysis, calculations and caveats Appendix E.6.

B2. Community reagent contribution

My response.

what can we do to increase the protein output of PetAse without so much misfolding? wIthout raising cost.

we will come back to chaperone, for a future round. Let’s stop here with our first finalized hypothesis and get ready for submittal

I identified the chaperone gap while asking how to raise PETase output, chose to defer it rather than fold it into this submission, and then selected GroEL/GroES as the reagent to propose.

Feedback. GroEL/GroES is proposed for the reducing regime because it is the only identified mechanism that addresses a quantity the present menu cannot move — every reagent that helps PETase helps by raising total titer, leaving the misfolded fraction unchanged. It is also unproven for this substrate and ATP-dependent, and the proposal states both limits rather than claiming a guaranteed gain.

→ Worked analysis, calculations and caveats Appendix E.7.

B3. Forum participation

My response.

make a brief draft of a forum post that summarizes my tool development approach with an example. The initial tool was built in Claude Science without code management. (Week 3). Week 4 introduces a code framework to be introduced.

What I did. Specified the subject and framing of the post, and joined the forum page.

Forum post (draft).

Building a reaction configurator before writing a codebase

For Week 3 I built an interactive CFPS configurator instead of working from a spreadsheet — reagent menu, volume and increment constraints, exact cost arithmetic, magnesium speciation, guardrails, and a folding and kinetics simulator. Every composition I submitted came out of it.

One example of why that mattered. The assigned oxidising plate for Reteplase carries 5 mM cysteine. Running it as a baseline tripped a free-thiol guardrail — in a DSB regime cysteine acts as a reductant. Removing it fixed disulfide pairing and made the DsbC we were paying for unnecessary $5.66 → $0.027 per reaction. The transferable part is the order. Removing DsbC alone looks wrong until cysteine is fixed first, so one-variable-at-a-time testing would have rejected the right answer.

This version was built conversationally in Claude Science, with no repository and no tests. Week 4 moves it onto a proper code framework with version control.

Feedback. The post leads with the cysteine result because the transferable lesson is about the order of a multi-variable move, not about reteplase specifically. The Week 3 / Week 4 framing is accurate and worth stating publicly two of the errors corrected during this work — a g/L unit conversion and a folding prior wrongly multiplying a synthesis rate — are exactly the class a test suite catches and a conversation does not.

→ Numbers behind the worked example, and the full tooling note Appendix E.8.

Part C — Asimov Kernel (optional)

I did not attempt Part C. The supplied sequences were extracted and checked during Part B work, so the starting material exists.

C1. T7-compatible plasmids for cell-free expression

(status not attempted)

Sequences supplied by the assignment for sfGFP, PETase, and Reteplase. Note that the PETase and Reteplase sequences as given carry an N-terminal Strep-tag II (WSHPQFEK) followed by a TEV protease site (ENLYFQS), and both end in a C-terminal GGSGVSGWRLFKKIS extension; sfGFP instead carries the Strep-tag at its C-terminus. These features need to be preserved or deliberately removed in the plasmid design.

C2. Bonus — T7 helper plasmid to improve functional Reteplase yield

(status not attempted)

Candidate cargo categories general chaperones, disulfide-bond formation and isomerization machinery, peptidyl-prolyl isomerases.

Feedback. Not attempted. The three supplied sequences were extracted and verified during Part B (sfGFP 240 aa, PETase 309 aa, Reteplase 399 aa), and the tag architecture is noted above, so C1 has its starting material if revisited.

Use of AI

Model Claude Opus 5 (claude-opus-5), via Claude Science. One continuous session, 86 human-authored prompts and 319 code executions.

Summary. AI was used in three ways to build a provenance rubric separating exact arithmetic (cost, concentrations, free magnesium, pH, volumes, guardrails) from fitted heuristics (titer, folding priors) from illustrative constants (simulation timing); to run the homework questions Socratically — question asked plain, answered first, critiqued after; and to build the CFPS configurator used to design and test every composition submitted here. The rubric is why titer is never used to rank a design. The tool is where the results came from.

Actual prompts, verbatim

“just ask me the question so I can research and answer verbatim, then we will analyze and mentor”

“I would like to create a visual simulator of the kinetic response to a selected formula. using the calculator or now we will call it the CFPS configurator, add a new tab for training and modeling an interactive simulation of the molecular compounds. It can be very abstract and illustrative at first, but based on actual metrics and values, as well as assumptions made in this activity.”

“for A3, now that we know Mg is important, and is low cost but only provides catalyst, and that kinetic Km sets the floor, we need to look at more impactful tuning levers, that have more kinetic impact AND less cost. GMP seems to be the best focus area to pursue. Let’s test the theory with calculations.”

“let’s compare a more aggressive move on reteplace. make some multiple variable moves to see if we can get cost down in comparison to energy and kinetics”

“what is the minimum amount of folding we can expect before the choice is not a good candidate”

Where the prompts led. The Socratic prompt produced A1–A3. The simulator prompt produced the configurator and, through it, the kinetics and folding modules. The GMP prompt was tested and came back partly supported — right that nucleotide form is the largest lever class, wrong that GMP ranks first. The multi-variable prompt produced the cysteine-as-reductant result. The folding-floor prompt set the assay threshold used to accept the reteplase design.

Appendix — worked analysis, by question

The main-body answers above are deliberately short. This appendix carries the worked reasoning, calculations, figures and caveats behind them.

E.1 — A1 potassium vs magnesium glutamate

The contrast is between the cations, not the salts. Potassium glutamate and magnesium glutamate share the same anion, so nothing that distinguishes them can be attributed to glutamate. Glutamate is the counter-ion of choice for both because it mimics the E. coli cytoplasm, and it is not inert — it is also an energy source via oxidative deamination into the TCA cycle, which is why a formulation of potassium glutamate, nucleotide monophosphates and amino acids can make protein with no sugar and no PEP at all. But that contribution is common to both reagents. The real question is K⁺ versus Mg²⁺.

What magnesium does. Mg²⁺ is a catalytic and structural cofactor occupying discrete, saturable sites. It supplies the two metal ions in the T7 RNA polymerase active site — one positioning and activating the attacking 3′-OH, the other coordinating the β,γ-phosphates and stabilizing the departing pyrophosphate. It bridges the 30S and 50S ribosomal subunits, holds the tertiary core of every tRNA together, and is required by the aminoacyl-tRNA synthetases and the translational GTPases. It is also half of the substrate Mg·ATP is the physiological species, so without magnesium the nucleotides are present but chemically inert.

Magnesium is explicitly not an energy source. The energy comes from phosphoanhydride bonds — those in the NTPs themselves and in whatever secondary donor regenerates them (PEP, maltose, maltodextrin, glucose, or glutamate). Magnesium is a catalyst it lowers activation barriers, is not consumed, and contributes no thermodynamic driving force. If anything it reduces the free energy released per nucleotide hydrolysed, since ΔG°′ for ATP hydrolysis becomes less negative as free Mg²⁺ rises.

What potassium does. K⁺ sets bulk ionic strength and reproduces the cytoplasmic potassium environment. It tunes translation-initiation fidelity and the strength of nonspecific protein–nucleic-acid electrostatics. This is a bulk solution property acting through Debye screening — a smooth, monotonic function of ionic strength — rather than occupancy of a defined site.

Why the concentrations differ between compositions chelation. Chelation is the binding and sequestration of a metal ion. Nucleotides chelate magnesium roughly 11, which means what the machinery experiences is free Mg²⁺, not the magnesium written on the recipe. The size of that sink depends on the energy system in my simulator’s engine, NTPs carry a magnesium-chelation weight of 1.0 against 0.3 for NMPs and 0.05 for inorganic phosphate, over a lysate-supplied baseline of ~3.45 mM. (A fourth coefficient for polyphosphate, mg_chelate_poly = 1.5, is defined in the coefficient file but is not applied by the engine’s freeMagnesium() function, which adds the polyphosphate term raw — so its effective weight is 1.0. I checked the source rather than the coefficient table; none of the formulations compared here contain a polyphosphate chelator, so no number in this answer depends on it either way.) A high-phosphate PEP+NTP formulation therefore has to add substantially more total magnesium than a low-phosphate NMP formulation to put the same free Mg²⁺ in front of the ribosome.

A speciation calculation makes the size of the effect concrete at 8 mM total magnesium glutamate, a high-phosphate PEP+NTP load leaves ~1.0 mM free Mg²⁺ while a low-phosphate NMP load leaves ~6.8 mM — roughly a 7-fold difference from identical added magnesium.

Two further sources of between-composition variance each lysate prep carries its own endogenous magnesium — Olsen et al. report an S30 buffer of 14 mM magnesium acetate and 60 mM potassium acetate — and the chelation landscape shifts during the reaction as NTPs are consumed and phosphate accumulates. Olsen et al. accordingly had to determine new optimum magnesium concentrations for each lysate concentration they tested.

Potassium has no comparable sequestration sink, so added potassium is essentially free potassium, and published potassium concentrations cluster far more tightly than magnesium ones.

Which is more sensitive magnesium, for four reasons that stack.

1. Site occupancy versus a bulk property. Function is steeply nonlinear in the occupancy of a saturable site near its binding constant; it is gradual in ionic strength.
2. Opposing failure modes make a peak rather than a plateau. Too little magnesium and ribosomal subunits dissociate, tRNA misfolds and the polymerase loses catalysis; too much and translational fidelity drops, mRNA secondary structure blocks initiation, and Mg-phosphate precipitates. Two distinct mechanisms closing in from either side give a sharp optimum. Potassium’s failure modes arrive gradually, and glutamate as counter-ion buffers the high end.
3. Chelation amplifies error. Free Mg²⁺ is the difference between two comparable large numbers, so a small fractional change in what is added produces a larger fractional change in what is available — I calculate amplification factors of ~1.6–1.9 under phosphate load against ~1.1 without, and that conclusion is robust across a 16-fold range of assumed binding constants. Potassium’s amplification is ~1.0 by construction.
4. Concentration scale. Magnesium operates near 10 mM and potassium near 130 mM, so equal absolute pipetting error is a ~13-fold larger fractional perturbation for magnesium. Under this project’s 25 nL dispensing granularity, one increment of a 100 mM stock into 20 µL is 1.25% of a magnesium setpoint but 0.10% of a potassium setpoint.

One apparent counter-example, resolved. Olsen et al. screened 1,231 formulations and arrived at a minimal active system comprised only of potassium glutamate, nucleotide monophosphates and amino acids — supplemental magnesium glutamate was among the components that did not improve yield on individual add-back. That is not evidence that magnesium is insensitive. Sensitivity is the steepness of yield against concentration near the optimum; it is not the same as needing supplementation. Magnesium is essential but already supplied by the lysate, and the same authors still had to re-determine its optimum for every lysate concentration. Notably, all of that work was on sfGFP, which has no disulfide bonds — so none of this magnesium behaviour has anything to do with disulfide chemistry.

Design consequences I am carrying into Part B. Magnesium glutamate costs fractions of a cent, which makes it a free tuning variable I can titrate it densely across compositions in a way I cannot afford with CTP, GTP, UTP, NAD or coenzyme A. But cheapness is not a licence to add more — the dose is set by the optimum, not by the price. And because NMPs chelate magnesium far less than NTPs, retuning magnesium is the obligatory second step of any NTP→NMP cost substitution GTP at $39.34/mL against GMP at $0.533/mL is a 74-fold saving that silently moves the magnesium optimum the moment it is taken.

Caveat on the numbers the speciation model above uses literature-typical order-of-magnitude binding constants rather than values measured in this session. The ~7-fold free-Mg²⁺ gap is robust to that uncertainty; the absolute millimolar values should not be quoted as measured.

E.2 — A2 PEP+NTP vs Ribose+NMP

Each name contains two slots, not one. Phosphoenolpyruvate is a phosphoryl donor; NTP is a nucleotide. Ribose is a pentose and carbon source; NMP is a nucleotide at a lower level of phosphorylation. So each formulation names one energy term and one nucleotide term PEP+NTP is “high-energy donor plus fully phosphorylated nucleotides,” and Ribose+NMP is “carbon/pentose source plus partially phosphorylated nucleotides.” Framing the contrast as transcription-energy versus translation-energy does not survive the accounting below.

Why the transcription/translation split fails. Translation consumes NTPs too, and it consumes far more of them than transcription does. Charging a tRNA costs 2 high-energy phosphate equivalents (ATP → AMP + PPi), EF-Tu delivery costs 1 GTP and EF-G translocation costs 1 GTP — 4 equivalents per peptide bond. For sfGFP (240 residues) at the 2.4 g/L titer Olsen et al. report, that is 85.3 mM of phosphate equivalents for translation alone. By contrast, each transcript is read many times, so the nucleotides polymerised into mRNA are a small fraction of the budget at 100 copies translated per transcript, pre-purchasing NTPs instead of phosphorylating NMPs saves roughly 1.6% of the translation demand (and between 0.3% and 31% across a 500-to-5 range of ribosome loading). Pre-made nucleotides are therefore a cost and kinetics decision, not an energy-budget decision.

Neither formulation escapes in-situ metabolism. PEP at the 30 mM of a PANOx-SP-type recipe supplies only about 39% of that 85.3 mM translation demand, so even the “pre-made” formulation depends on downstream metabolism of the pyruvate PEP leaves behind for roughly 2.6× more energy than PEP itself carries. The honest contrast is how much in-situ work is required, not whether any is.

Pool versus flux — the asymmetry that matters. The NTP line items in a recipe are pool sizes, not total consumption. A ~3.75 mM total NTP pool has to turn over about 23× to meet an 85 mM demand, recharged continuously by the energy system. This splits the four nucleotides into two classes

At 100 copies per transcript, a 0.85 mM supply of CTP or UTP exceeds stoichiometric demand (~0.17 mM) by about 5×. Those two are the first place to cut.

But the floor is kinetic, not stoichiometric. T7 RNA polymerase follows saturation kinetics, so the limit is the concentration the active site sees, not the total mass available. Because nucleotides are consumed, concentration falls during the run, and supplying exactly the stoichiometric demand drives the rate to zero before the demand is met. Starting at 1× Km retains only 28% of the initial transcription rate by the end of the run; starting at 5× Km retains 97%. Roughly 3–5× Km is the operating choice, and that headroom is what the apparent “excess” actually is. Two further complications a dual-use nucleotide’s floor is set by whichever of its several consumers has the highest Km, and the true substrate is Mg·NTP, so free magnesium and nucleotide supply are not independent knobs.

Byproducts and pH — where the two routes diverge most. PEP donating its phosphate yields pyruvate and releases inorganic phosphate stoichiometrically. That phosphate chelates magnesium, inhibits the reaction, and drops the pH — the three problems that motivated the Cytomim system’s move away from high-energy phosphate donors in the first place. It also raises the apparent Km through product inhibition, so the kinetic floor rises while nucleotide concentration falls two effects converging, which is why batch PEP+NTP reactions have a finite lifetime. Ribose and sugar routes instead accumulate organic acids through glycolysis, which also lowers pH but without the stoichiometric phosphate burst — so buffering capacity (HEPES-KOH, formate) becomes the governing design choice rather than phosphate management.

Cost — the reason any of this matters here. GTP costs $39.34/mL against GMP at $0.533/mL, a 74-fold difference, and CTP, GTP and UTP all sit in the $28–39/mL band. Since the scoring metric is cost per gram of functional protein, nucleotide provisioning is the largest lever available after lysate. What the 74-fold premium buys is real, though faster onset, higher flux, and independence from the lysate’s kinase and salvage capacity — which is a batch-to-batch variable, since those enzymes have to survive lysis and clarification in sufficient activity.

The dichotomy is not even exhaustive. Olsen et al. screened 1,231 formulations and arrived at a minimal active system of potassium glutamate, nucleotide monophosphates and amino acids — no sugar and no PEP at all. The energy in that system comes from glutamate itself, via oxidative deamination into the TCA cycle, and they further showed nucleoside triphosphates could be produced from nitrogenous bases and ribose. So the real design space is not “PEP+NTP or Ribose+NMP” but a continuum of how much nucleotide and phosphate provisioning you delegate to the lysate.

Design consequences I am carrying into Part B. Cut the pure-transcription nucleotides (CTP, UTP) hardest; protect the flux carriers (ATP, GTP); substitute NMPs where the lysate can phosphorylate them; respect a 3–5× Km headroom rather than cutting to stoichiometric demand; buffer for the acid load of whichever energy route is chosen; and retune magnesium after every nucleotide change, because NMPs chelate magnesium at roughly a third the weight of NTPs.

Caveats. Copies translated per transcript and the polymerase Km under these conditions are both unmeasured, and they are the two parameters the argument pivots on — the percentages above are an order-of-magnitude ledger, not measurements. The 0.85 mM per-NTP supply figure is a PANOx-SP-type value that could not be verified against its primary source (see decision log entry 2). Energy stoichiometry (4 equivalents per peptide bond, 1 per nucleotide polymerised, 2 per NMP→NTP conversion) is standard biochemistry; the 2.4 g/L titer is Olsen et al.’s reported value.

E.3 — A3 PANOx-SP vs Olsen RFopt, and the lever test

Reagent-class comparison.

The classes of reagent removed matter more than any concentration change RFopt deletes the secondary energy substrate, all four triphosphates, and four separate cofactors, and pays for it with higher potassium glutamate, higher amino acids, more buffer, and a reliance on lysate kinase and salvage activity.

Variable-cost decomposition (exact). PANOx-SP PEP 29.0%, coenzyme A 22.8%, GTP 15.1%, UTP 14.5%, CTP 10.7%, NAD 5.5%, ATP 0.8%. RFopt CMP 22.6%, AMP 17.6%, UMP 15.0%, ribose 11.3%, potassium glutamate 10.9%, GMP 9.5%. Note the inversion — in the cheap formulation the nucleotides are still the largest line, but the whole variable budget is 19× smaller, so the fixed lysate cost ($0.02/reaction) becomes 75% of the all-in total.

Substitution ladder on PANOx-SP (exact cost, exact free Mg²⁺).

Caveats. Reagent cost, final concentrations, free magnesium, volumes and the 25 nL increment are exact outputs of the engine. The magnesium factor and the 4.6 mM optimum come from the engine’s titer heuristic, which the tool itself documents as having negative leave-one-out R² against eleven published formulations and which must not be used to rank untested designs — so the factor is directional evidence that the substitution moves magnesium off-optimum, not a yield prediction. The substitutions hold nucleotide concentration constant in mM; the engine applies a 0.86 supply weight to NMPs, so matched mM is a ~14% reduction in nucleotide-supply equivalents that a real screen would need to check. Nucleosides and nucleobases are cheaper still per mM but arrive on 0.025 M stocks — 800 nL per mM against 200 nL for NMPs — so they consume the 11,000 nL variable budget four times faster and are gated on ribose.

E.4 — B1a sfGFP composition, full specification

The composition. Source well RFopt (2026) · reducing regime · 8,675 nL of 11,000 designable · $0.0263007 per 20 µL reaction. Removed from the source well added cysteine (5 → 1 mM, base buffer only).

Feedback. Five reagents moved; twelve stayed at reference. The magnesium cut is the mechanistically strongest of them — free Mg²⁺ falls 8.11 → 4.63 mM onto the modelled optimum and the magnesium factor goes 0.587 → 0.9999 for fractions of a cent. The AMP trim is the one that earns twice it makes the four nucleotides equimolar (balance 0.951 → 1.0000) and, by removing chelation load, is what carries free Mg²⁺ onto that optimum at no cost. The cost result here is negligible — variable cost falls 6.7% but all-in only 0.49%, because 92% of a reaction is lysate, DNA template and base buffer, which are not designable. Validity 0 errors, 0 guardrail failures, one inherited warning (nmp_precipitate, total NMP 8.50 mM against a 5 mM threshold). MODEL output, not used for ranking total titer 3.2845 g/L, active fraction 1.0000, active titer 3.2845 g/L.

E.5 — B1b PETase composition, full specification

The composition. Source well RFopt (2026) · reducing regime · 8,675 nL of 11,000 designable · $0.0265907 per 20 µL reaction. Removed from the source well added cysteine (5 → 1 mM, base buffer only).

Feedback. The decision not to diverge from sfGFP is the substantive one here, and it is supported rather than assumed all 51 reducing-compatible reagents on the menu were tested at two volumes each and none changed the active fraction off 0.4295. Decomposing fold_prior × (0.85 + 0.15·p_pair) shows why — the disulfide term spans only 1.14× across its entire reachable range while the unanchored prior’s ±1 sd spans 3.0×. The crystal structure agrees that redox chemistry is not the lever the single disulfide sits 26 Å from the catalytic serine, so it is a stability feature. The 57% loss is an unmeasured parameter, not a formulation fault, and the cheapest way to close it is one 30-minute p-nitrophenyl read, not a reagent. Validity 0 errors, 0 guardrail failures, nmp_precipitate inherited. MODEL output total titer 3.2845 g/L, active fraction 0.4295, active titer 1.4107 g/L.

E.6 — B1c Reteplase composition, full specification

The composition. Source well RFopt (ox.) (2026) · oxidizing / DSB regime · 9,350 nL of 11,000 designable · $0.0273835 per 20 µL reaction. Removed from the source well added cysteine (5 → 1 mM, base buffer only); DsbC (5 µM → absent).

Feedback. The multi-variable approach was the right call and the evidence says so removing DsbC alone looks like a bad move until cysteine is fixed first, so one-at-a-time testing would have rejected the correct answer. At the plate’s assigned 5 mM, cysteine acts as a reductant in the DSB regime — modelled pairing is p_pair 0.3674, which back-solves to 0.56× the replicate-safe assay threshold, i.e. the plate as specified cannot produce a scoreable well. With added cysteine removed, pairing reaches p_pair 0.5132 with no DsbC at all, above the 0.4452 an earlier design bought with 3.5 µM. The cut is stoichiometrically safe 18 cysteines at 0.5–2 g/L protein need 0.23–0.92 mM against the base buffer’s 1.0 mM. Cost falls 206.7×, and it is one reagent — DsbC was 99.97% of that plate’s variable cost. Caveat that belongs with the number the engine treats the 9 disulfides as pairing independently (active = p_pair⁹), while the AlphaFold model of tPA shows three coupled modules of three, so the true active fraction is 7–55× higher than reported and 0.0025 is a floor. Validity 0 errors, 0 guardrail failures, nmp_precipitate inherited. MODEL output total titer 2.0364 g/L, active fraction 0.0025, active titer 0.005029 g/L.

E.7 — B2 GroEL/GroES community reagent proposal

Feedback. The proposal below is GroEL/GroES for the reducing regime. It is the one mechanism identified that addresses the quantity shown to be immovable with the present menu.

double-ring GroEL plus the GroES lid), for the reducing regime.

Rationale. It is the only mechanism I could identify that would move the quantity my own analysis showed is currently immovable. PETase loses 57% of synthesised protein to misfolding, and that loss is a folding-outcome term, not a concentration term. I tested all 51 reducing-compatible reagents on the present menu at two volumes each none of them changed the active fraction off 0.4295. Every reagent that helps at all helps by raising total titer, so active and misfolded protein rise together and the ratio is untouched. The menu has no chaperone at all — DsbC exists but is gated to the oxidising regime, where it addresses disulfide pairing rather than conformational folding.

Why GroEL/ES specifically. Its documented effect is on the soluble/active fraction rather than on expression level, which is exactly the term that is missing. Over-expressing GroEL/GroES increased the fluorescence of GFP-expressing cells without changing the amount of GFP protein made, by raising the fraction that was soluble rather than aggregated — a yield effect, not a titer effect. In a cell-free system specifically, adding GroEL–GroES to nascent CCR5 chains increased both the rate and the yield of functional folding where spontaneous folding was slow and inefficient. On a defined substrate (DapA) the chaperonin accelerated folding ~30-fold and carried the yield to ~100%, and co-expression of both subunits raised soluble aconitase yield to ~39% where GroEL alone did nothing — so both components are needed; GroEL alone is not enough.

How the decision was reached. Not by assumption. The sequence was (1) decompose PETase’s active fraction into fold_prior × (0.85 + 0.15·p_pair) and sweep each part — the disulfide term spans only 1.14× across its entire reachable range while the prior’s ±1 sd spans 3.0×; (2) confirm from the crystal structure (4CG1, 1.4 Å) that the single disulfide sits 26 Å from the catalytic serine, so it is a stability feature and redox chemistry cannot be the answer; (3) sweep every reducing-compatible reagent and find none that moves the fraction. Only then did “the menu is missing a reagent class” become the conclusion rather than the premise.

Honest caveats, which belong in the proposal. GroEL/ES assists roughly 10% of newly synthesised E. coli proteins, so PETase may simply not be a client — this is a hypothesis to test, not a guaranteed gain. The chaperonin is ATP-dependent, and our composition deliberately carries no ATP (only AMP, recharged in situ), so a dosing study would need to confirm the adenylate pool supports the cycle. It can also slow folding of proteins that fold well without it, and in at least one membrane-protein study GroES actively reduced folding yield. Finally, it is a large, costly protein reagent — any menu addition needs a cost per mL before it can be scored against a cost-per-gram objective.

Supporting research (links)

• Chi et al., Folding of newly translated membrane protein CCR5 is assisted by the chaperonin GroEL-GroES — cell-free system, rate and yield of functional folding. https//www.ncbi.nlm.nih.gov/pmc/articles/PMC4653635/
• Georgescauld et al., GroEL/ES chaperonin modulates the mechanism and accelerates the rate of TIM-barrel domain folding — ~30-fold acceleration, ~100% yield on DapA. https//pmc.ncbi.nlm.nih.gov/articles/PMC4071350/
• Tang et al., Essential role of the chaperonin folding compartment in vivo — GroEL alone does not improve yield; GroEL + GroES raises soluble aconitase to ~39%. https//pmc.ncbi.nlm.nih.gov/articles/PMC2396394/
• Horwich & Fenton, Chaperonin-assisted protein folding a chronologue, Quarterly Reviews of Biophysics — the soluble-fraction effect on GFP, and the view that preventing aggregation matters more than accelerating folding. https//www.cambridge.org/core/journals/quarterly-reviews-of-biophysics/article/chaperoninassisted-protein-folding-a-chronologue/99CCB61641B4C118EAA879F177E2AC4B

A note that connects to my own design. The CCR5 cell-free work used Brij-35 to keep nascent chains soluble. Brij-35 is already on the menu, and in my own scan it was the single best gain-per-dollar reagent available (+5.4% active protein for $0.0000108 — 7,105 g/L per dollar). The model books that benefit as a titer multiplier; the literature suggests at least part of it is an anti-aggregation effect, i.e. a fraction effect the model cannot represent. That is a second argument for adding a folding-outcome term to the scoring, not just a folding reagent to the menu.

E.8 — B3 numbers behind the forum example, and the tooling note

The cysteine result, in full. The assigned RFopt (ox.) plate carries 5 mM cysteine. Sweeping cysteine with DsbC held fixed gives modelled pairing of p_pair 0.3674. Back-solving the app’s own assay calibration — 540 RFU per µM AMC, 260 RFU blank, 0.42 µM AMC/min per µM enzyme, a 480-minute window and a lowest calibrated standard of 0.39 µM AMC — puts that at 0.56× the replicate-safe threshold, meaning the plate as specified cannot produce a scoreable well. Sweeping DsbC with cysteine at base level instead gives p_pair 0.5132 with no DsbC at all, above the 0.4452 an earlier design had bought with 3.5 µM of it.

Why the order matters. DsbC was compensating for a problem cysteine was creating. Evaluated alone, removing DsbC lowers modelled pairing and looks like a bad move; evaluated after cysteine is corrected, it is free. A strict one-factor-at-a-time protocol would therefore have rejected the correct design. This is the general case against single-lever screening when two reagents interact through the same term — here, the thiol penalty.

Cost decomposition. DsbC at 5 µM costs 1,000 nL on a 0.1 mM stock and accounts for 99.97% of that plate’s variable cost ($5.632 of $5.634). Removing it takes the reaction from $5.6595134 to $0.0273835 all-in, a 206.7× reduction. It also resolves a budget problem the plate as specified needs 11,750 nL against an 11,000 nL allowance, so it is not loadable as written.

Stoichiometric check before the cut. Reteplase carries 18 cysteine residues. At 0.5–2 g/L total protein that is 0.23–0.92 mM of demand, against 1.0 mM supplied by the base buffer — so removing added cysteine leaves the requirement covered. The engine does not model cysteine as a limiting amino acid, only as a thiol, so it would have permitted the cut regardless; the check is what makes it defensible.

Tooling note. The Week 3 configurator was built conversationally with no repository, version control or test suite. That was a reasonable trade for a first pass — the tool grew as the questions did, and the folding simulator answered questions that were not anticipated when it was started. The cost of that trade is visible in the error record a g/L-to-mM unit conversion on the ribose and glucose stocks (a 3.3× overdose that was reported as correct), and a folding prior multiplying a synthesis rate, which silently produced zero protein for reteplase and half for PETase. Both were found by re-deriving results, not by any automated check. A parity test now runs on every build of the folding module and reproduces the engine’s active fraction to within 2×10⁻¹⁵ — that test is what caught the second error, and it is the pattern Week 4’s code framework is intended to generalise.

E.9 — What is exact, what is modelled, and what is not used for ranking

Stated explicitly so the reader need not infer it.

The titer model’s leave-one-out R² on log titer is −0.26 with median fold error 1.456 across 11 reference formulations — worse than predicting the mean. That is the reason for the second row.

Open items carried forward, not resolved

1. nmp_precipitate warns on all three designs (total NMP 8.50 mM against a 5 mM threshold). Inherited from the reference plates. Clearing it costs ~24% of modelled titer to save 1.4% of variable cost, so the trade was refused.
2. Reteplase’s active fraction is a floor, not an estimate. The engine treats its 9 disulfides as pairing independently; the AlphaFold model of tPA shows three coupled modules of three, so the defensible exponent is between 3 and 9 and the true value is 7–55× higher. The exponent was left at 9 so all reference formulations stay comparable.
3. PETase’s fold_prior is unanchored at 0.50 ± 0.25. One 30-minute p-nitrophenyl read would replace it with a measurement.
4. Submission JSON field names are unverified against ginkgobioworks/autonomous-cfps; the repository was unreachable when the exporter was built.
5. The assignment cites DOI 10.1002/bit.20026 as PANOx-SP; that DOI resolves to the Cytomim paper. The PANOx-SP table used here came from the tool’s own reference record.
6. The tool lists reteplase at 355 aa; the supplied sequence is 399 aa (Strep-tag II / TEV construct). Flagged, not silently resolved.
7. A Brij-35 plus spermidine/putrescine combination raises active titer 18.2% for +$0.000211 per reaction. Deliberately held for a future round so the three levers under test keep clean attribution.

Citations

(status in progress)

• Olsen, M. L., Copeland, C. E., Sundberg, C. A., Aw, R., Shaver, Z. M., Rao, G., Swartz, J. R., Karim, A. S., & Jewett, M. C. (2026). Design-driven optimization of low-cost reagent formulations for reproducible and high-yielding cell-free gene expression. Nature Communications. DOI 10.1038/s41467-026-69605-8. Full text retrieved, open access.
• Smith, A. A., et al. (2026). Using a GPT-5-driven autonomous lab to optimize the cost and titer of cell-free protein synthesis (Ginkgo Bioworks × OpenAI). bioRxiv. DOI 10.64898/2026.02.05.703998. Not yet retrieved.
• Jewett, M. C., & Swartz, J. R. (2004). Mimicking the Escherichia coli cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. Biotechnology and Bioengineering, 86(1), 19–26. DOI 10.1002/bit.20026. Paywalled; abstract only. See decision log entry 2 — this is the Cytomim paper, not the PANOx-SP paper.
• Silverman, A. D., Karim, A. S., & Jewett, M. C. (2020). Cell-free gene expression an expanded repertoire of applications. Nature Reviews Genetics, 21, 151–170. DOI 10.1038/s41576-019-0186-3.
• Rasor, B. J., Vögeli, B., Landwehr, G. M., Bogart, J. W., Karim, A. S., & Jewett, M. C. (2021). Toward sustainable, cell-free biomanufacturing. Current Opinion in Biotechnology, 69, 136–144. DOI 10.1016/j.copbio.2020.12.012.

Decision log

1. A1 mechanism rejected. An initial framing that attributed differing potassium- and magnesium-glutamate concentrations to differing disulfide-bond requirements was discarded. K⁺ and Mg²⁺ are closed-shell, non-redox-active cations and do not participate in thiol oxidation; disulfide outcomes in this system are controlled by the DTT / IAM / GSSG-GSH / DsbC / Δgor variables enumerated in Section 2C. The retained explanation is free-Mg²⁺ buffering by phosphate and nucleotide load.

2. Assignment citation discrepancy, carried into A3. The assignment recommends “PANOx-SP (Jewett & Swartz 2004)” and gives DOI 10.1002/bit.20026, but that DOI resolves to the Cytomim paper — the pyruvate-driven, phosphate-free system assayed with chloramphenicol acetyltransferase at 700 µg/mL. PANOx-SP is a distinct formulation. A primary PANOx-SP source with an actual concentration table is still needed before A3 can be written. Do not describe PANOx-SP while citing this DOI.

3. Part A3 pair not yet selected. Choice is open between the yield-vs-cost contrast (PANOx-SP vs Olsen 2026) and the human-vs-AI contrast (Olsen 2026 vs Smith 2026), the latter being closer to the coopetition’s own question.

4. A1 second correction — magnesium is not an energy source. An intermediate framing held that magnesium “provides the reaction energy needed for NTPs.” Rejected the energy resides in phosphoanhydride bonds (NTPs and the secondary donor regenerating them), while Mg²⁺ is a non-consumed catalyst contributing no driving force — and rising free Mg²⁺ makes ΔG°′ of ATP hydrolysis less negative, so the claim fails in direction as well as kind. Retained instead Mg·NTP is the physiological substrate, so magnesium is what makes the nucleotides usable.

5. A1 — necessity distinguished from sensitivity. Being essential does not make a reagent sensitive (the 20 amino acids are essential with broad optima). The sensitivity argument rests on saturable-site occupancy, opposing high- and low-side failure modes, chelation amplification, and the ~13-fold fractional-precision disadvantage of operating at 10 mM rather than 130 mM.

6. A1 — cheapness is not a dosing argument. Magnesium glutamate costs fractions of a cent, which licenses dense titration across compositions, not a higher setpoint. Overshoot carries real penalties (fidelity loss, mRNA structure, Mg-phosphate precipitation). The cost lever is NTP→NMP substitution; magnesium is the variable that must be retuned to realise it.

7. Engine coefficient claim corrected. An earlier draft of A1 stated the engine applies a polyphosphate magnesium-chelation weight of 1.5. Reading freeMagnesium() in the engine source shows the polyphosphate term is added raw, so its effective weight is 1.0 and mg_chelate_poly is an unused coefficient. The claim is corrected in Appendix E.1. No number in Part A depended on it — none of the compared formulations contain a polyphosphate chelator — and the same error was fixed in the kinetics model so that its free-Mg²⁺ calculation now reproduces the engine to within 1e-9 on all four reference formulations.

8. PANOx-SP source resolved, and a concentration corrected. The configurator’s own reference-formulation record carries PANOx-SP in full (Mg-glutamate 8 mM, K-glutamate 130 mM, ATP 1.2 mM, CTP/GTP/UTP 0.85 mM each, PEP 30 mM, HEPES 57 mM, with cost $4,083/g). This supplies the concentration table A3 needs without relying on the mis-cited DOI in decision log entry 2. It also corrects an earlier draft figure PEP is 30 mM, not ~33 mM.

9. Answer format changed on author instruction. Main-body answers now lead with the author’s own claim in italic, followed by a brief rationale and the key learnings that shaped it. The full worked analysis moved to Appendix E so the submitted answers stay short and the supporting work remains auditable.

Week 4 - Lab 1 - Cloud Lab Cell Free Systems

Final Project